"Kept It Just Under 5 Billion Won to Avoid Disclosure": Lunit Executives' Shocking Share Sale Tactics That Betrayed Shareholders [At a Crossroads] Lunit ③
IPO Price Inflated by “Rosy Projections”
Executives Cash In Through “Trick” Share Sales as Stock Plummets
“No Rights Offering” Pledge Broken with New Capital Raise in the New Year
Controversy continues to surround the credibility of Lunit, which is conducting a large-scale rights offering allocated to existing shareholders. The company's projected net profit at the time of listing missed the mark by more than 100 billion won, and during that period, the management engaged in actions such as 'dubious' share sales, further disappointing shareholders. The current capital increase has also intensified the controversy, as it reverses the company's previous stance of having 'no such plans.'
According to the Financial Supervisory Service’s electronic disclosure system on March 4, Lunit was listed on the KOSDAQ market via the technology exception program on July 21, 2022. At the time, Lunit was a loss-making company, recording a net loss of 56.1 billion won, so its offering price was calculated by discounting future estimated net profits to present value.
The performance projections Lunit presented were dramatic. The company forecast that its losses would shrink to 24 billion won in 2023, turn a profit of 8.6 billion won in 2024, and record a net profit of 58.3 billion won in 2025. By converting these forecasts to 2022 present value and multiplying by the average price-earnings ratio (PER) of comparable companies, Lunit set its IPO target price at 44,000 to 49,000 won per share. Through this process, Lunit raised 36.5 billion won.
However, the actual results were dismal. Lunit posted a net loss of 36.8 billion won in 2023 and a net loss of 82.4 billion won in 2024. As of the end of the third quarter last year, the company had accumulated a net loss of 15 billion won. The reason the third quarter net loss appeared relatively small was because a gain of 81.3 billion won was recorded from the revaluation of convertible bond (CB) derivative financial liabilities due to a decline in share price, which did not result in any actual cash inflow. Excluding this, operating-related net losses would be even larger. In effect, the IPO price was 'inflated.'
In its latest securities registration statement, Lunit in fact admitted to having presented unreliable projections at the time of listing. The company cited the following as reasons for the wide gap between projections and actual results: errors in assumptions regarding global market penetration, insufficient understanding of hospital adoption structures, and misjudgment of the decision-making process in the pharmaceutical industry.
As a result, Lunit's share price declined as actual results diverged from expectations. Shareholders ultimately bore the brunt of the losses.
Meanwhile, Lunit’s management was criticized by shareholders for selling shares through ‘dubious’ means. On December 18, 2024, six executives, including CFO Park Hyunseong and CPO Paeng Kyunghyun, sold part of their holdings to a US-based fund management company via a block deal (off-hours large-volume trading).
Each executive sold 64,156 common shares at a price of 77,934 won per share. The value per individual was 4,999,933,704 won. In the market, the reason for setting the sale price below 5 billion won was pointed out as the 'insider trading pre-disclosure system.'
This system requires company executives and others to disclose the price and volume of transactions at least 30 days in advance if they trade 1% or more of the company’s shares, or if the transaction value exceeds 5 billion won, in order to prevent sharp declines in share price due to large insider sales. There is suspicion that the transaction amount was kept under 5 billion won so as not to notify shareholders in advance. Following this transaction, Lunit's share price plummeted.
Having lost shareholder trust, Lunit once again turned to shareholders for support. This was less than a year after publicly declaring that there would be 'no rights offering.' A Lunit representative explained, "When we said at last March's regular general meeting that there was no plan for a rights offering, we meant there would be no additional rights offering at least in 2025."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Lunit representative added, "Even if there have been changes in market conditions and adjustments to the company's strategic direction, we bear a heavy sense of responsibility for failing to achieve the results promised at the time of listing and disappointing our shareholders. With this rights offering, we aim to transform our financial structure and reach break-even by the end of this year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.